(CHE) Chemed - NYSE
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 5.791m USD | Total Return: -16.2% in 12m
Avg Turnover: 97.7M
EPS Trend: 49.2%
Qual. Beats: 1
Rev. Trend: 98.1%
Qual. Beats: 1
Warnings
Choppy
Tailwinds
No distinct edge detected
Chemed Corporation operates two distinct business segments: VITAS Healthcare, which provides hospice and palliative care services through multidisciplinary teams of physicians, nurses, aides, social workers, clergy, and volunteers, and Roto-Rooter, which offers plumbing, drain cleaning, excavation, and water restoration services to residential and commercial customers via company-owned branches, independent contractors, and franchisees. The company is headquartered in Cincinnati, Ohio, was incorporated in 1970, and trades on the NYSE under the ticker CHE.
Chemeds business model is notable for its unusual pairing of a healthcare services segment with a home services franchise operation. U.S. hospice providers like VITAS are predominantly reimbursed through the Medicare Hospice Benefit, which subjects the segment to regulated per-diem payment rates, while Roto-Rooter generates revenue through a mix of direct operations and franchising.
- Medicare hospice reimbursement cuts pressure VITAS margins
- Roto-Rooter weather-driven demand boosts residential service revenue
- Share repurchases return capital as buyback authorization continues
| Net Income: 259.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.25 > 0.02 and ΔFCF/TA 6.31 > 1.0 |
| NWC/Revenue: -1.86% < 20% (prev 8.51%; Δ -10.37% < -1%) |
| CFO/TA 0.29 > 3% & CFO 443.7m > Net Income 259.8m |
| Net Debt (365.8m) to EBITDA (418.1m): 0.87 < 3 |
| Current Ratio: 0.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.7m) vs 12m ago -7.38% < -2% |
| Gross Margin: 30.32% > 18% (prev 34.82%; Δ -4.50% > 0.5%) |
| Asset Turnover: 155.8% > 50% (prev 144.2%; Δ 11.59% > 0%) |
| Interest Coverage Ratio: 101.4 > 6 (EBIT TTM 352.4m / Interest Expense TTM 3.48m) |
| A: -0.03 (Total Current Assets 274.1m - Total Current Liabilities 321.4m) / Total Assets 1.54b |
| B: 1.96 (Retained Earnings 3.01b / Total Assets 1.54b) |
| C: 0.22 (EBIT TTM 352.4m / Avg Total Assets 1.63b) |
| D: 1.23 (Book Value of Equity 848.0m / Total Liabilities 687.8m) |
| Altman-Z'' = 8.94 = AAA |
| DSRI: 0.74 (Receivables 215.5m/285.9m, Revenue 2.54b/2.49b) |
| GMI: 1.15 (GM 34.82% / 30.32%) |
| AQI: 1.42 (AQ_t 0.73 / AQ_t-1 0.52) |
| SGI: 1.02 (Revenue 2.54b / 2.49b) |
| TATA: -0.12 (NI 259.8m - CFO 443.7m) / TA 1.54b) |
| Beneish M = -2.86 (Cap -4..+1) = A |
As of June 27, 2026, the stock is trading at USD 463.28 with a total of 93,779 shares traded. Over the past week, the price has changed by +6.19%, over one month by +6.08%, over three months by +24.72% and over the past year by -16.21%.
Current recommended Stop Loss: 437.70 (which is 5.5% or 2 ATR below the current price).
Chemed has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy CHE.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 446.5 | -3.6% |
P/E Trailing = 23.8139
P/E Forward = 18.0505
P/S = 2.2795
P/B = 6.8292
P/EG = 1.8039
Revenue TTM = 2.54b USD
EBIT TTM = 352.4m USD
EBITDA TTM = 418.1m USD
Long Term Debt = 91.2m USD (from longTermDebt, last quarter)
Short Term Debt = 41.3m USD (from shortTermDebt, last quarter)
Debt = 382.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 145.7m
Net Debt = 365.8m USD (calculated: Debt 382.7m - CCE 16.9m)
Enterprise Value = 6.16b USD (5.79b + Debt 382.7m - CCE 16.9m)
Interest Coverage Ratio = 101.4 (Ebit TTM 352.4m / Interest Expense TTM 3.48m)
EV/FCF = 16.33x (Enterprise Value 6.16b / FCF TTM 377.1m)
FCF Yield = 6.13% (FCF TTM 377.1m / Enterprise Value 6.16b)
FCF Margin = 14.84% (FCF TTM 377.1m / Revenue TTM 2.54b)
Net Margin = 10.23% (Net Income TTM 259.8m / Revenue TTM 2.54b)
Gross Margin = 30.32% ((Revenue TTM 2.54b - Cost of Revenue TTM 1.77b) / Revenue TTM)
Gross Margin QoQ = 30.25% (prev 32.22%)
Tobins Q-Ratio = 4.01 (Enterprise Value 6.16b / Total Assets 1.54b)
Interest Expense / Debt = 0.91% (Interest Expense 3.48m / Debt 382.7m)
Taxrate = 25.55% (89.2m / 348.9m)
NOPAT = 262.4m (EBIT 352.4m * (1 - 25.55%))
Current Ratio = 0.85 (Total Current Assets 274.1m / Total Current Liabilities 321.4m)
Debt / Equity = 0.45 (Debt 382.7m / totalStockholderEquity, last quarter 848.0m)
Debt / EBITDA = 0.87 (Net Debt 365.8m / EBITDA 418.1m)
Debt / FCF = 0.97 (Net Debt 365.8m / FCF TTM 377.1m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.93% (Net Income 259.8m / Total Assets 1.54b)
RoE = 25.33% (Net Income TTM 259.8m / Total Stockholder Equity 1.03b)
RoCE = 31.56% (EBIT 352.4m / Capital Employed (Equity 1.03b + L.T.Debt 91.2m))
RoIC = 21.18% (NOPAT 262.4m / Invested Capital 1.24b)
WACC = 6.18% (E(5.79b)/V(6.17b) * Re(6.54%) + D(382.7m)/V(6.17b) * Rd(0.91%) * (1-Tc(0.26)))
Discount Rate = 6.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.56 | Cagr: -4.78%
[DCF] Terminal Value 77.97% ; FCFF base≈352.3m ; Y1≈403.8m ; Y5≈594.3m
[DCF] Fair Price = 646.2 (EV 8.94b - Net Debt 365.8m = Equity 8.58b / Shares 13.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 49.22 | EPS CAGR: 2.92% | SUE: 1.18 | # QB: 1
Revenue Correlation: 98.10 | Revenue CAGR: 6.12% | SUE: 1.00 | # QB: 1
EPS current Quarter (2026-06-30): EPS=5.62 | Chg30d=-0.09% | Revisions=-20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=6.02 | Chg30d=-0.04% | Revisions=-20% | Analysts=4
EPS current Year (2026-12-31): EPS=24.35 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+13.0% | GrowthRev=+6.4%
EPS next Year (2027-12-31): EPS=26.91 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+10.5% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: +25%